^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HK2 overexpression

    i
    Other names: HK2, Hexokinase 2, Muscle Form Hexokinase, Hexokinase Type II, Hexokinase-2, Hexokinase-B, Hexokinase-2, Muscle, HKII, HXK2
    Entrez ID:
    4194; 3099
    Related biomarkers:
    Mutation
    CNA
    over3years
    Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance. (PubMed, Oxid Med Cell Longev)
    Acquired EGFR-TKI-resistant lung cancer cell lines (HCC827, H1993, and H292 cells with acquired resistance to gefitinib or erlotinib) were used for cell-based studies. Long-term treatment with EGFR-TKIs causes reactivation of mitochondrial metabolism, resulting in vulnerability to OXPHOS inhibitor such as phenformin. We propose a new therapeutic option for NSCLC with acquired EGFR-TKI resistance that focuses on cancer metabolism.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • HK2 (Hexokinase 2)
    |
    HK2 overexpression
    |
    erlotinib • gefitinib